896 related articles for article (PubMed ID: 26188977)
1. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem-resistant-only Pseudomonas aeruginosa infection in patients formerly infected by carbapenem-susceptible strains.
Tsai MH; Wu TL; Su LH; Lo WL; Chen CL; Liang YH; Chiu CH
Int J Antimicrob Agents; 2014 Dec; 44(6):541-5. PubMed ID: 25264129
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Valderrama SL; González PF; Caro MA; Ardila N; Ariza B; Gil F; Álvarez C
Biomedica; 2016 Feb; 36(0):69-77. PubMed ID: 27622627
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
7. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
[TBL] [Abstract][Full Text] [Related]
8. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Dong SX; Wang JT; Chang SC
J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
10. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
Kim CH; Kang HY; Kim BR; Jeon H; Lee YC; Lee SH; Lee JC
J Microbiol; 2016 Jan; 54(1):44-49. PubMed ID: 26727901
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
[TBL] [Abstract][Full Text] [Related]
13. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
14. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.
Zhang Y; Chen XL; Huang AW; Liu SL; Liu WJ; Zhang N; Lu XZ
Emerg Microbes Infect; 2016 Mar; 5(3):e27. PubMed ID: 27004762
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa.
Tsao LH; Hsin CY; Liu HY; Chuang HC; Chen LY; Lee YJ
J Microbiol Immunol Infect; 2018 Jun; 51(3):359-366. PubMed ID: 28988663
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome.
Jeong SJ; Yoon SS; Bae IK; Jeong SH; Kim JM; Lee K
Diagn Microbiol Infect Dis; 2014 Oct; 80(2):130-5. PubMed ID: 25112900
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.
Lin KY; Lauderdale TL; Wang JT; Chang SC
J Microbiol Immunol Infect; 2016 Feb; 49(1):52-9. PubMed ID: 24662016
[TBL] [Abstract][Full Text] [Related]
18. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center.
Huang YC; Wu PF; Lin YT; Wang FD
J Microbiol Immunol Infect; 2019 Apr; 52(2):304-311. PubMed ID: 30097388
[TBL] [Abstract][Full Text] [Related]
20. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
Peña C; Suarez C; Gozalo M; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2012 Mar; 56(3):1265-72. PubMed ID: 22155832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
